Literature DB >> 26810650

In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.

Michael D Huband1, Mariana Castanheira2, Robert K Flamm2, David J Farrell2, Ronald N Jones2, Helio S Sader2.   

Abstract

Thein vitroantibacterial activities of ceftazidime-avibactam and comparator agents were evaluated using reference broth microdilution methods against 1,743Pseudomonas aeruginosaisolates collected in 2014 from 69 U.S. medical centers, representing each of the nine census regions. Ceftazidime-avibactam demonstrated potent activity againstP. aeruginosa, including many isolates not susceptible to ceftazidime, meropenem, and piperacillin-tazobactam. In each of the nine census regions, ceftazidime-avibactam demonstrated the highest percentage of susceptible isolates.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26810650      PMCID： PMC4808178          DOI： 10.1128/AAC.03056-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Emergence of KPC-producing Pseudomonas aeruginosa in the United States.

Authors:  Laurent Poirel; Patrice Nordmann; Emilie Lagrutta; Timothy Cleary; L Silvia Munoz-Price
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

2.  First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase.

Authors:  Maria Virginia Villegas; Karen Lolans; Adriana Correa; Juan Nicolas Kattan; Jaime A Lopez; John P Quinn
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

Review 3.  Pseudomonas aeruginosa: all roads lead to resistance.

Authors:  Elena B M Breidenstein; César de la Fuente-Núñez; Robert E W Hancock
Journal:  Trends Microbiol       Date:  2011-06-12       Impact factor: 17.079

4.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

5.  Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Andrea M Hujer; T Nicholas Domitrovic; Kristine M Hujer; Kelly N Hurless; Marion Tuohy; Geraldine Hall; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

6.  In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.

Authors:  Henry Li; Mark Estabrook; George A Jacoby; Wright W Nichols; Raymond T Testa; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

7.  Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).

Authors:  Helio S Sader; Mariana Castanheira; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2015-06-17       Impact factor: 2.803

8.  Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study.

Authors:  Yi-Yun Liu; Yang Wang; Timothy R Walsh; Ling-Xian Yi; Rong Zhang; James Spencer; Yohei Doi; Guobao Tian; Baolei Dong; Xianhui Huang; Lin-Feng Yu; Danxia Gu; Hongwei Ren; Xiaojie Chen; Luchao Lv; Dandan He; Hongwei Zhou; Zisen Liang; Jian-Hua Liu; Jianzhong Shen
Journal:  Lancet Infect Dis       Date:  2015-11-19       Impact factor: 25.071

9.  Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.

Authors:  Mariana Castanheira; Sarah E Farrell; Kevin M Krause; Ronald N Jones; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

Review 10.  Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections.

Authors:  Karen Bush
Journal:  Crit Care       Date:  2010-06-29       Impact factor: 9.097
View more
  16 in total

1.  Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.

Authors:  Helio S Sader; Michael D Huband; Mariana Castanheira; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

2.  Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Wright W Nichols; Gregory G Stone; Paul Newell; Helen Broadhurst; Angela Wardman; Merran MacPherson; Katrina Yates; Todd Riccobene; Ian A Critchley; Shampa Das
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

Review 3.  Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

Authors:  Andre Arizpe; Kelly R Reveles; Shrina D Patel; Samuel L Aitken
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

Review 4.  Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Thomas J Walsh
Journal:  Transpl Infect Dis       Date:  2017-10-25       Impact factor: 2.228

Review 5.  Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Authors:  Lynn Nguyen; Joshua Garcia; Katherine Gruenberg; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2018-06-06       Impact factor: 3.725

Review 6.  Underscoring interstrain variability and the impact of growth conditions on associated antimicrobial susceptibilities in preclinical testing of novel antimicrobial drugs.

Authors:  David A Sanchez; Luis R Martinez
Journal:  Crit Rev Microbiol       Date:  2018-12-06       Impact factor: 7.624

Review 7.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

Review 8.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

9.  In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014).

Authors:  Wright W Nichols; Boudewijn L M de Jonge; Krystyna M Kazmierczak; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 10.  Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.

Authors:  Kellie J Goodlet; David P Nicolau; Michael D Nailor
Journal:  Ther Clin Risk Manag       Date:  2016-12-01       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.